Overview
The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy
Status:
Completed
Completed
Trial end date:
2013-09-01
2013-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to see if it is safe and effective to give alpha lipoic acid in people with cardiac autonomic neuropathy(CAN). Cardiac autonomic neuropathy(CAN) affects the nerves that control heart rate and blood flow to the heart in people with diabetes. CAN may cause problems with the rhythm of the heartbeat or decrease blood flow to the heart.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
The Catholic University of KoreaTreatments:
Thioctic Acid
Criteria
Inclusion Criteria :- Established Cardiac Autonomic Neuropathy in type 2 diabetes.
- aged 20 years to 80 years
- Capable of giving informed consent
Exclusion Criteria :
- History of other significant disease such as the nerve system (Parkinson's disease,
epilepsy, multiple sclerosis), hepatic disease, hypothyroid, etc Other medical
condition or treatment likely to affect the autonomic nerve system
- HbA1C > 11%
- Not controlled hypertension (SBP≥160mmHg, DBP≥100mmHg)
- Diagnosed ketoacidosis within 4 weeks
- Unstable cardiac disease (unstable angina or myocardial infarction )
- Pregnancy
- Involvement in other clinical trial in last 4 weeks
- Known or suspected sensitivity to trial products